Yale Medicine School: New Drug Combination Shown Effective for Patients With Advanced Ovarian Cancer
February 14, 2022
February 14, 2022
NEW HAVEN, Connecticut, Feb. 14 (TNSJou) -- Yale School of Medicine issued the following news:
A new study led by researchers at Yale Cancer Center and the University of Maryland Greenebaum Comprehensive Cancer Center shows ixabepilone plus bevacizumab (IXA+BEV) is a well-tolerated, effective combination for treatment of platinum/taxane-resistant ovarian cancer compared to ixabepilone (IXA) alone. The data shows it also may significantly extend both progression-free survival and ove . . .
A new study led by researchers at Yale Cancer Center and the University of Maryland Greenebaum Comprehensive Cancer Center shows ixabepilone plus bevacizumab (IXA+BEV) is a well-tolerated, effective combination for treatment of platinum/taxane-resistant ovarian cancer compared to ixabepilone (IXA) alone. The data shows it also may significantly extend both progression-free survival and ove . . .